Hired & Retired: From big pharma to mid-sized leadership
This month featured executives making the switch from big pharma to take on leadership positions at mid-sized companies.
It is not exactly a surprise that those individuals at the bigger pharmaceutical companies have to move on to find a position higher up the leadership chain or to join the C-suite – there are only a limited number of seats at the table at the top 20 companies.
As a result, this month saw Sanofi lose the head of its vaccine unit, right in the middle of the novel coronavirus pandemic, to take a CEO position elsewhere.
The scarcity of talent at the top level of the cell and gene therapy also led to Celgene seeing a leader in the area leave them to take a CEO position elsewhere.
